Cabergoline Improves Metabolic Status in Hyperprolactinemia

A single-center, observational study suggests that 6 months of treatment with the dopamine agonist cabergoline improves cardiometabolic measures in patients with a prolactinoma and hyperprolactinemia.
First Look

source https://www.medscape.com/viewarticle/974577?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?